Similarly, potent and selective ROS1 inhibitors were shown to have high rates of intracranial ORR (79–89%) in phase I/II clinical trials in patients with NSCLC positive for ROS fusions [92,93] (Table 2). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.